` BFRI (Biofrontera Inc) vs S&P 500 Comparison - Alpha Spread

BFRI
vs
S&P 500

Over the past 12 months, BFRI has underperformed S&P 500, delivering a return of -32% compared to the S&P 500's 10% growth.

Stocks Performance
BFRI vs S&P 500

Loading
BFRI
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BFRI vs S&P 500

Loading
BFRI
S&P 500
Difference
www.alphaspread.com

Performance By Year
BFRI vs S&P 500

Loading
BFRI
S&P 500
Add Stock

Competitors Performance
Biofrontera Inc vs Peers

S&P 500
BFRI
LLY
JNJ
NOVO B
ROG
Add Stock

Biofrontera Inc
Glance View

Market Cap
5.4m USD
Industry
Pharmaceuticals

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

BFRI Intrinsic Value
3.126 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top